Published in Rev Recent Clin Trials on September 01, 2007
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc (2010) 1.29
Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One (2010) 1.27
NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol (2010) 1.21
Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl (2011) 1.18
Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer. J Am Chem Soc (2009) 1.17
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother (2009) 1.08
'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol (2010) 1.03
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother (2011) 1.02
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate (2009) 1.00
Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug Chem (2013) 0.97
Molecular imaging with nucleic acid aptamers. Curr Med Chem (2011) 0.96
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.93
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget (2011) 0.92
Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One (2012) 0.92
Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen. Angew Chem Int Ed Engl (2015) 0.87
Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep (2013) 0.87
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep. Pharmaceuticals (Basel) (2014) 0.87
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. J Drug Target (2013) 0.86
Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med (2015) 0.85
Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view. Front Oncol (2012) 0.81
An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy. Adv Healthc Mater (2012) 0.79
Enhancing cellular cancer vaccines. Immunotherapy (2009) 0.77
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces (2016) 0.77
A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer. Oncotarget (2016) 0.75
Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers. ISRN Oncol (2011) 0.75
Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res (2006) 5.90
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem (2004) 3.49
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem (2006) 1.44
Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol Biol Cell (2004) 1.33
Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest (2004) 1.30
Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res (2012) 1.22
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res (2003) 1.22
Repression of Na,K-ATPase beta1-subunit by the transcription factor snail in carcinoma. Mol Biol Cell (2003) 1.22
Na-K-ATPase regulates tight junction permeability through occludin phosphorylation in pancreatic epithelial cells. Am J Physiol Gastrointest Liver Physiol (2006) 1.19
Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Mol Cancer Ther (2010) 1.13
Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res (2005) 1.11
Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer (2003) 1.10
Na,K-ATPase inhibition alters tight junction structure and permeability in human retinal pigment epithelial cells. Am J Physiol Cell Physiol (2003) 1.09
Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol (2002) 1.07
Na,K-ATPase and epithelial tight junctions. Front Biosci (Landmark Ed) (2009) 1.07
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
Interactions of tight junctions with membrane channels and transporters. Biochim Biophys Acta (2007) 1.06
Janus model of the Na,K-ATPase beta-subunit transmembrane domain: distinct faces mediate alpha/beta assembly and beta-beta homo-oligomerization. J Mol Biol (2006) 1.05
Targeted treatment of prostate cancer. J Cell Biochem (2007) 1.03
Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther (2004) 1.02
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate (2004) 1.02
Multiple functions of Na,K-ATPase in epithelial cells. Semin Nephrol (2005) 1.00
In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther (2011) 0.99
HPAF-II, a cell culture model to study pancreatic epithelial cell structure and function. Pancreas (2004) 0.99
Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp Cell Res (2011) 0.98
alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. Mol Cancer Ther (2008) 0.97
Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma. J Urol (2007) 0.97
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem (2005) 0.95
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol Cancer Ther (2005) 0.94
Na,K-ATPase beta1-subunit increases the translation efficiency of the alpha1-subunit in MSV-MDCK cells. Mol Biol Cell (2004) 0.93
Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate (2003) 0.93
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate (2002) 0.93
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res (2007) 0.93
Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem (2002) 0.91
Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm (2012) 0.91
The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol (2002) 0.88
Protein expression based multimarker analysis of breast cancer samples. BMC Cancer (2011) 0.88
Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One (2011) 0.88
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther (2008) 0.88
Dysfunction of ouabain-induced cardiac contractility in mice with heart-specific ablation of Na,K-ATPase beta1-subunit. J Mol Cell Cardiol (2009) 0.85
Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature. Microvasc Res (2006) 0.85
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate (2003) 0.85
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol (2007) 0.85
Na,K-ATPase β-subunit cis homo-oligomerization is necessary for epithelial lumen formation in mammalian cells. J Cell Sci (2012) 0.82
Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin. Cancer Chemother Pharmacol (2009) 0.81
Expression of Na,K-ATPase beta-subunit in transformed MDCK cells increases the translation of the Na,K-ATPase alpha-subunit. Ann N Y Acad Sci (2003) 0.81
Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol Lung Cell Mol Physiol (2012) 0.79
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen. Mol Cancer Ther (2006) 0.79
Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells. Mol Cancer Ther (2013) 0.79
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. Int J Oncol (2007) 0.78
2-5A ligands--a new concept for the treatment of prostate cancer. Nucleosides Nucleotides Nucleic Acids (2007) 0.76
Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists. Nucleosides Nucleotides Nucleic Acids (2012) 0.76
Clearing up the confusion over the glutamate carboxypeptidase II gene. Am J Med Genet A (2004) 0.75
Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma. Mol Cancer Ther (2014) 0.75